{"disease":{"id":"brca-mutated-ovarian-cancer","name":"brca mutated ovarian cancer"},"drugs":{"marketed":[{"drug_id":"rucaparib","indication_name":"Maintenance treatment of BRCA-mutated recurrent ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rubraca","generic_name":"RUCAPARIB","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PARP-1, PARP-2, PARP-3","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Rucaparib inhibits PARP enzymes, causing DNA damage and cancer cell death, especially in cells with BRCA1/2 deficiencies."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01874353","title":"Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":327,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT03402841","title":"Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":279,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT02476968","title":"To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":181,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT01853306","title":"A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT03943173","title":"Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery","phase":"EARLY_PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":15,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06065059","title":"Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"Tango Therapeutics, Inc.","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}